Loading clinical trials...
Loading clinical trials...
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
* Efficacy data not collected or analyzed * Safety and tolerability of Xalatan assessed NA
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Alexandria, Egypt
Pfizer Investigational Site
Jeddah, Saudi Arabia
Pfizer Investigational Site
Umm Al Quwain City, United Arab Emirates
Start Date
July 1, 2005
Primary Completion Date
December 1, 2007
Completion Date
December 1, 2007
Last Updated
February 25, 2021
1,289
ACTUAL participants
Xalatan 0.005% eye drops
DRUG
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441